Skip to main content

Table 1 Response rate as assessed at Day 168 in the REACH3 trial

From: A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

 

Ruxolitinib (%)

Best alternative therapy (%)

Overall response

49.70

25.61

No response

41.21

68.29

Dead

9.09

6.10

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us